Spruce Point Capital is short Resideo Technologies, Inc. (NYSE: REZI) and calls for an independent investigation into the accuracy of its financial reporting and accounting. As a troubled spin-off from Honeywell in 2018, Resideo has failed to achieve its long-term financial goals, suffers from years of organizational complexity, and has failed to fix lingering technology issues. Spruce Point provides analysis suggesting Resideo has engaged in value-destructive M&A with questionable financial reporting to bolster the appearance of earnings growth, with the First Alert (2022) and Snap One Holdings (2024) acquisitions being particularly troubled. The announced split-up is viewed as a red herring to distract from weakening competitive positioning, diminished growth vectors, and growing accounting strains. Resideo is now precariously levered at 5.5x (up from 3.3x in 2018). Spruce Point sees 25-50% downside to approximately $17.64-$26.45 per share.
We did not write this report. We catalogued it. The underlying research was published by Spruce Point Capital. The Forensic Ledger does not endorse its conclusions. Always read the original document.
The Core Allegation
Resideo Technologies, Inc. (NYSE: REZI) has failed to achieve its long-term financial goals and Spruce Point calls for an independent investigation into the accuracy of its financial reporting and accounting.
A Troubled Honeywell Spin-Off
As a troubled spin-off from Honeywell in 2018, Resideo has:
- Suffered from years of organizational complexity
- Failed to fix lingering technology issues
- Failed to achieve its long-term financial goals
Value-Destructive M&A
Resideo has engaged in value-destructive M&A with questionable financial reporting to bolster the appearance of earnings growth. The following acquisitions are particularly troubled:
- First Alert (2022) — initial foray into large-scale acquisitions
- Snap One Holdings (2024) — continued the pattern
These acquisitions paper over REZI's long-term goal failures and intensify its financial problems.
The Split-Up Red Herring
With few, if any, levers left to spin upside potential, REZI is now doing an about face and claims the best way to unlock value is to split-up the Company.
Spruce Point thinks this is a red herring. The real problems are:
- Weakening competitive positioning
- Diminished growth vectors
- Growing accounting strains
These can't simply be solved by a split-up.
Cash Flow Never Lies
Ignore REZI's Non-GAAP results. Cash flow never lies and Spruce Point believes it is the ultimate arbiter of REZI's failures.
Precarious Leverage
While Spruce Point applauds REZI for finally settling its obligations to Honeywell in July 2025, the Company is now left:
- Precariously levered at 5.5x (up from 3.3x in 2018)
- With significant financial uncertainties ahead
Sputtering Growth
REZI's promoted avenues of growth appear to be sputtering. With the removal of the Honeywell obligation and the split-up announcement, there are few, if any, upside catalysts to expand REZI's multiple beyond this historically high level.
The Downside
Based on a sum-of-the-parts analysis, Spruce Point believes the share price is materially overvalued:
- 25% – 50% downside risk
- Target range: approximately $17.64 – $26.45 per share
- Expected to underperform the market and its related industries
subsequent events
- 2018Resideo spins off from Honeywell
“A troubled spin-off from Honeywell in 2018”
- 2022Resideo acquires First Alert — initial large-scale acquisition
“Its initial foray into large scale acquisitions was First Alert in 2022”
- 2024Resideo acquires Snap One Holdings
“Acquisitions of First Alert and Snap One Holdings in 2022 and 2024, respectively, to be particularly troubled”
- 2025-07Resideo settles obligations to Honeywell
“Left precariously levered at 5.5x (up from 3.3x in 2018)”
- 2026-01-27Spruce Point publishes short report on Resideo
“We see 25% – 50% downside risk to approximately $17.64 – $26.45 per share”
Source — https://www.sprucepointcap.com/research/resideo-technologies-inc
Not investment advice. This dossier summarizes a third-party short report. The Forensic Ledger did not produce the underlying research and does not endorse its conclusions. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.